Possible Vaccine for Virus Linked to Type 1 Diabetes

Docent Varpu Marjomäki from the University of Jyväskylä has studied for a long time the infection mechanisms of enterovirus. Researchers produced a new vaccine for enteroviruses to provide protection against type 1 diabetes. Courtesy of University of Jyväskylä

According to many observations, certain virus infections may play a part in the autoimmune attack that leads to type 1 diabetes. Researchers at Karolinska Institutet and at the universities of Jyväskylä and Tampere have now produced a vaccine for these viruses in the hope that it could provide protection against the disease. The study is published 6 May 2020 in the scientific journal Science Advances.

While an estimated 50,000 Swedes and 50, 000 Finns live with type 1 diabetes (sometimes known as juvenile diabetes) the causes of the disease remain unknown. There is a genetic component, but also environmental factors are needed for the disease to develop. One such factor believed to be significant in type 1 diabetes is infections caused by an extremely common group of enteroviruses. The sub-group in question is the Coxsackie B (CVB) family and it comprises of six strains that can give rise to the common cold. However, CVBs can also cause more serious infections leading to diseases including myocarditis and meningitis.

According to many scientific observations, one hypothesis suggests that CVBs play a part in the development of type 1 diabetes. The disease is characterized by an autoimmune attack on the insulin-producing beta cells in the pancreas and it is possible that the virus infection somehow initiates this attack by the immune system.

Epidemiological studies, in which children with a genetic risk profile for type 1 diabetes were monitored by blood tests over a period of many years, indicate that CVBs could be a pathogenic contributor. There are also autopsy observations suggesting that CVBs might be involved in the development of type 1 diabetes. This, however, remains hypothetical as the connection is yet to be proven, albeit it is a hypothesis that is well-established amongst diabetes researchers.

Researchers at Karolinska Institutet, Tampere University and University of Jyväskylä in Finland have now produced a vaccine that protects against all six known strains of CVB. The CVB serotypes to be used in the vaccine had been originally detected in the research performed in Vactech Oy in Tampere. The vaccine was tested in different animal models and was shown to protect mice infected with CVB from developing virus-induced type 1 diabetes.

The researchers then tested the vaccine in rhesus monkeys that have very similar genetics to humans. In these animals, the vaccine worked well and induced antibodies to CVB suggesting it could protect against the virus. An American pharmaceutical company is now going to perform clinical studies where they will test the vaccine in human subjects.

Assuming the vaccine is safe in initial trails, the plan is to use the vaccine in children with a genetic risk profile for type 1 diabetes. The researchers write that if the number of children that develop type 1 diabetes decreases after vaccination or if none develop the disease it will confirm that CVB are a triggering environmental factor.

"Our hope is that the vaccine will prove effective against CVB infections and that it will then be possible to administer it to children," says Malin Flodström-Tullberg, professor of type 1 diabetes at the Department of Medicine, Karolinska Institutet, Huddinge, and the study's corresponding author.

"It would be fantastic if the cases of type 1 diabetes that we currently suspect are caused by the Coxsackievirus could be prevented, though it's impossible right now to say what percentage of type 1 diabetes cases would be effected. At the same time, the vaccine would give protection against myocarditis, which can have a more severe course in both children and adults, and against many kinds of cold, which keep many people away from school and work."

"The research groups associated with this work have done fruitful collaboration already a longer time, to understand the infection mechanisms of enteroviruses and to develop vaccines and antivirals to combat enteroviruse infection", says Docent Varpu Marjomaki from the University of Jyvaskyla. Marjomaki is working also at Nanoscience Center at the University of Jyvaskyla.

The study was financed with grants from Business Finland, the Academy of Finland, the Swedish Childrens' Diabetes Fund and the Strategic Research Programme in Diabetes at Karolinska Institutet. The US pharmaceutical company conducting the tests is Provention Bio, for which Malin Flodström Tullberg is scientific advisor. The patent for the vaccine has been in-licensed from the Finnish company Vactech Oy, of which Heikki Hyöty, professor at Tampere University and co-author of the study, was one of the founders.

12 Comments on "Possible Vaccine for Virus Linked to Type 1 Diabetes"

  1. This is really some awesome advice. Keep it up, my colleagues would love this.

  2. Hello 🙂 I bookmarked this site. Thanks heaps for this!… if anyone else has anything, it would be much appreciated.

  3. Hi – in actuality great site you have created. I enjoyed reading this posting. I did want to publish a remark to tell you that the design of this content is very aesthetically delightful. I used to be a graphic designer, now I am a copy editor. I have always enjoyed functioning with information processing systems and am trying to learn code in my free time.

  4. Having tried out every last fat burning diet plan that you can buy I think I have found the best plan for me.

  5. Hello 🙂 nice information, many thanks to the author. it is incomprehensible to me now, but in general, the usefulness and significance is overwhelming. thanks again and good luck!

  6. Its pretty interesting that the mainstream media has changed the way it looks at this recently dont you think? What used to neve be brought up or discussed has changed. Frankly it is about time we see a change.

  7. It is easy to completely call at your loyalty during the function you are writing. Everybody hopes for far more amorous internet writers as you which are usually not anxious to express that feel. Constantly do your main cardiovascular system..

  8. I think this is among the most significant information for me. And im glad reading your article. But want to remark on some general things, The website style is wonderful, the articles is really excellent : D. Good job, cheers

  9. Dzięki za ten wpis jest ciekawy i inspirujący. Tylko nie zasypiaj gruszek w popiele czekam na więcej.

  10. Thank you for the post on your blog. Do you provide an RSS feed?

  11. We wanted to share with you the best way impressed I’m in your service and product. I really wanted one to know that am almost certainly going to order extra of my own stuff via you due to their low fee in freight along with the speedy shipping and delivery. Just wanted to tell someone the event I just simply had onto your site. My newbie and ?t had been so effortless. Everything was now and quite a confusion. Free WebWebmaster

  12. I had this content saved some time before but my computer crashed. I have since gotten a new one and it took me a while to come across this! I also in fact like the design though.

Leave a comment

Your email address will not be published.


*